Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study
December 23, 2020 08:00 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327 and RECCE® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a well-accepted model of infection Intranasal administration of...
Recce Pharmaceuticals Provides Business Update
December 21, 2020 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its...
Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE® Anti-Infectives
November 23, 2020 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent...
Recce Pharmaceuticals Announces Encouraging Preliminary Results from Antiviral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2
November 11, 2020 08:00 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327, a synthetic anti-infective showed encouraging efficacy in an in-vitro screening assay against SARS-CoV-2 virusRECCE® 327 showed encouraging inhibition and is advancing...
Recce Pharmaceuticals Announces Third-Quarter 2020 Financial Results and Provides Operational Highlights
October 21, 2020 08:00 ET
|
Recce Pharmaceuticals
Highlights: Strong cash balance of A$25.68 million after successful capital raising Phase I human clinical trial to evaluate RECCE® 327 (I.V.) in healthy subjects at leading clinical research...
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Study Evaluating Topical Spray-On Synthetic Antibiotic RECCE® 327 on Chronic Burn Wounds
October 19, 2020 08:00 ET
|
Recce Pharmaceuticals
Highlights: Study will assess safety and efficacy of RECCE® 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two week period Study anticipated to be...
Recce Pharmaceuticals Appoints Synthetic Anti-infectives Expert Michele Dilizia as Chief Scientific Officer
October 14, 2020 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing New Classes of Synthetic Anti-Infectives, is pleased to announce the Board of...
Recce Pharmaceuticals and Murdoch Children’s Research Institute to Evaluate RECCE® 435 Against Helicobacter pylori Stomach Bacteria
September 30, 2020 08:53 ET
|
Recce Pharmaceuticals
Highlights: Murdoch Children’s Research Institute to evaluate the in-vivo antimicrobial activity of RECCE® 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies...
Recce Pharmaceuticals Completes Capital Raising of $27.95 Million
September 23, 2020 09:04 ET
|
Recce Pharmaceuticals
Highlights: Commitments received for a placement of A$27,950,000 at $1.30 per share Significant participation from overseas and Australian blue-chip institutional investors This capital raising will...
Recce Pharmaceuticals Announces Positive & Concentration-dependent Efficacy of RECCE® Compounds Against COVID-19 in International Study
September 10, 2020 08:00 ET
|
Recce Pharmaceuticals
Highlights RECCE® 327 (R327) & RECCE® 529 (R529) compounds have shown concentration-dependent reductions in the SARS-CoV-2 (COVID-19) virus in an in-vitro study using organoids made from human...